{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:51:13Z","timestamp":1790200273180,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":206,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Advances in Hematology"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    The international cooperation between GATLA and AHOPCA with the support of St. Jude led to the adoption of the OEPA\/COPDAC as a strategy to improve outcomes in high risk (HR) patients with HL. This study also includes the ABVD regimen for intermediate risk (IR) and low risk (LR) patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Patients were stratified by predefined risk assignment. HR was defined as a disease in stages II B, III B, and IV. Modality treatment: LR: ABVD\u2009\u00d7\u20094\u2009\u00b1\u2009IFRT (20\u2009Gy); IR: ABVD\u2009\u00d7\u20096\u2009\u00b1\u2009IFRT (20\u2009Gy); and HR: OEPA\u2013COPDAC\u2009+\u2009IFRT (20\/25\u2009Gy). The staging and response were reviewed in a periodic discussion of presentation of cases in the group. Eligibility for radiotherapy: LR patients in partial response (PR) after 4 ABVD and IR patients in PR after 2 ABVD received IFRT. All HR patients received IFRT at 20 (complete response (CR)) or 25\u2009Gy (PR) depending on the response achieved after the first two OEPA cycles.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    From November 2012 to June 2022, 203 pediatric patients were enrolled. A total of 171 patients were eligible in this analysis. HR: 98 patients (57.3%), IR: 52 patients (30.4%), and LR: 21 patients (12.3%). More than half of the patients were in stages III and IV and more than half also presented B symptoms. The response evaluation was performed by PET\/CT in 147\/171 patients (86%). A total of 68\/171 patients (40%) did not received radiotherapy. Radiotherapy was omitted in 95% of the LR patients and 70% of the IR patients. The 10\u2010year OS was 95% (90.7\u201397.6) for the 171 patients and 93% (85.3\u201396.4) for HR patients. The 10\u2010year EFS was 91% (85.2\u201394.2) for the 171 patients and 87.8% (79.5\u201392.9) for HR patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The international cooperation made it possible to significantly improve the outcomes of patients with advance disease in Argentina compared with our previous experience (7\u2010PHD\u201096: COPP\u2013ABV\u2009\u00d7\u20096\u2009+\u2009IFRT Bulky Disease or PR (20\/25\u2009Gy): 5yOS: 85%, 5yEFS: 67%), reduce the number of patients who required radiotherapy, and reproduce the European experience for HR patients in a totally different context.\n                  <\/jats:p>","DOI":"10.1155\/ah\/5453729","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T10:49:27Z","timestamp":1753526967000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk\u2010Stratified and Response\u2010Adapted Therapy for Pediatric Hodgkin Lymphoma in Argentina: The GATLA Experience"],"prefix":"10.1155","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-543X","authenticated-orcid":false,"given":"David","family":"Veron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Streitenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Matus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Negri Aranguren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Morell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Terrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Mauricio","family":"Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"de Alarcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Dibar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Makiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"e_1_2_12_1_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28562"},{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/2333794x231223266"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30022-x"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25698"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200011000-00004"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24905"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30257"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.26.9381"},{"key":"e_1_2_12_9_2","article-title":"Is It Possible to Work Together in Latin America? The Latin American Consortium (CLEHOP) Experience With Hodgkin Lymphoma (HL)","volume":"232","author":"Veron D.","year":"2020","journal-title":"Klinische P\u00e4diatrie"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.4853"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1371133"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.3816\/clm.2004.n.016"},{"key":"e_1_2_12_13_2","article-title":"The GATLA (Argentinian Collaborative Group) Experience Through International Cooperation in Pediatric Hodgkin Lymphoma (HL)","volume":"232","author":"Veron D.","year":"2020","journal-title":"Klinische P\u00e4diatrie"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135945"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1989.7.11.1630"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.02.9850"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_12_18_2","article-title":"Outcome of Pediatric Relapsed\/Refractory Hodgkin Lymphoma Patients in 2 Different Latin American Settings: AHOPCA (Asociaci\u00f3n De Hemato-Oncolog\u00eda Pedi\u00e1trica De Centro Am\u00e9rica) and GATLA (Grupo Argentino De Tratamiento De Leucemia Aguda)","volume":"232","author":"On behalf of Members of Ahopca","year":"2020","journal-title":"Klinische P\u00e4diatrie"},{"key":"e_1_2_12_19_2","volume-title":"Ciudad Aut\u00f3noma De Buenos Aires: Instituto Nacional Del C\u00e1ncer","author":"Registro Oncopedi\u00e1trico Hospitalario Argentino","year":"2015"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000000943"}],"container-title":["Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ah\/5453729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/ah\/5453729","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ah\/5453729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:21:21Z","timestamp":1773768081000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/ah\/5453729"}},"subtitle":[],"editor":[{"given":"Suraiya","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/ah\/5453729"],"URL":"https:\/\/doi.org\/10.1155\/ah\/5453729","archive":["Portico"],"relation":{},"ISSN":["1687-9104","1687-9112"],"issn-type":[{"value":"1687-9104","type":"print"},{"value":"1687-9112","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"5453729"}}